Bill · S. 4332· Senate(119-S-4332)
Medication Competition Act
- Introduced
- 4/16/2026
- Last activity
- 4/16/2026 — Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Sponsored by
- Maggie Hassan
- Cosponsors
- - 0 - 1
- Introduced
- In Committee
What this bill would do
The Medication Competition Act requires the Secretary of Health and Human Services to determine exclusivity periods for licensed biological products. It amends the Public Health Service Act to include specific requirements for listing these periods. The bill establishes different timelines for products licensed before or after the date of enactment. Specifically, it mandates how the Secretary must publish exclusivity periods for both first interchangeable biological products and reference products. This ensures that the Secretary includes expiration dates on published lists within specific timeframes.
Yes· 3 of 5
Does this make what the government does easier for the public to see?+4
The bill mandates specific timelines for the Secretary of Health and Human Services to publish expiration dates for biological product exclusivity.
Does this give people more protection from unfair business practices?+3
The bill increases transparency regarding biological product exclusivity periods, which can assist in market competition and consumer awareness.
Would households on low incomes be better off under this?+2
Increased transparency in biological product exclusivity can lead to greater market competition and lower drug costs for consumers.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Increased Transparency for Biological Products: The bill requires the Secretary to include applicable exclusivity periods on a published list for first interchangeable biological products (Section 2, (I)(aa) and (I)(bb)). This ensures that information regarding how long a product has exclusivity is made known once an expiration date can be known.
-
Timely Information for New Products: For biological products licensed on or after the date of enactment, the Secretary must include the expiration date of the exclusivity period for reference products not later than 30 days after licensure (Section 2, (II)(aa)). This provides quick access to expiration data for new products.
-
Systematic Updates for Existing Products: For products licensed before the enactment of this act, the Secretary is required to include the expiration date of exclusivity periods for reference products on the list within 2 years (Section 2, (II)(bb)). This ensures that older products are eventually integrated into the updated listing system.
Potential Negative Impacts for People
- No negative impacts or burdens are explicitly stated in the provided text.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Governance And Ideology
- Improves Government Transparency+4
- Demographic And Interest Groups
- Good For Low Income Households+2Good For Urban Residents+1
- Economy And Finance
- Improves Consumer Protection+3
- Healthcare
- Reduces Prescription Drug Costs+2
- 4/16/2026
- Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 1 Cosponsor added.
- Introduced in Senate
Ted BuddRepublican · North Carolina